CN1579415A - 玉足海参糖胺聚糖针剂及其制备方法 - Google Patents
玉足海参糖胺聚糖针剂及其制备方法 Download PDFInfo
- Publication number
- CN1579415A CN1579415A CN 200410038284 CN200410038284A CN1579415A CN 1579415 A CN1579415 A CN 1579415A CN 200410038284 CN200410038284 CN 200410038284 CN 200410038284 A CN200410038284 A CN 200410038284A CN 1579415 A CN1579415 A CN 1579415A
- Authority
- CN
- China
- Prior art keywords
- supernatant
- injection
- precipitate
- treatment
- centrifugalize
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 6
- 241000251511 Holothuroidea Species 0.000 title abstract 4
- 241000951471 Citrus junos Species 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 238000002347 injection Methods 0.000 claims abstract description 52
- 239000007924 injection Substances 0.000 claims abstract description 52
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 208000005189 Embolism Diseases 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241001213462 Holothuria leucospilota Species 0.000 claims description 38
- 239000006228 supernatant Substances 0.000 claims description 30
- 239000002244 precipitate Substances 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000012043 crude product Substances 0.000 claims description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 101800000263 Acidic protein Proteins 0.000 claims description 4
- 235000011056 potassium acetate Nutrition 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000007445 Chromatographic isolation Methods 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims 2
- 239000000243 solution Substances 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 238000000151 deposition Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 34
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008336 microcirculatory blood flow Effects 0.000 description 2
- 210000003446 pia mater Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical group OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410038284 CN1579415A (zh) | 2004-05-20 | 2004-05-20 | 玉足海参糖胺聚糖针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410038284 CN1579415A (zh) | 2004-05-20 | 2004-05-20 | 玉足海参糖胺聚糖针剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1579415A true CN1579415A (zh) | 2005-02-16 |
Family
ID=34582126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410038284 Pending CN1579415A (zh) | 2004-05-20 | 2004-05-20 | 玉足海参糖胺聚糖针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1579415A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102993324A (zh) * | 2012-12-30 | 2013-03-27 | 青岛市市立医院 | 一种提取玉足海参糖胺聚糖的方法 |
CN102993325A (zh) * | 2012-12-30 | 2013-03-27 | 青岛市市立医院 | 一种从刺参中提取糖胺聚糖的方法 |
CN103536621A (zh) * | 2012-07-11 | 2014-01-29 | 上海开润生物医药有限公司 | 海参糖胺聚糖在制备治疗冠脉综合症药物中的应用 |
CN104147039A (zh) * | 2013-05-13 | 2014-11-19 | 上海开润生物医药有限公司 | 黑海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
CN104147040A (zh) * | 2013-05-13 | 2014-11-19 | 上海开润生物医药有限公司 | 海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
US20150051165A1 (en) * | 2012-03-05 | 2015-02-19 | Shanghai Kairun Biology Medicine Limited Liability Company | Application of depolymerized holothurian gylcosaminoglycans (dhg) in preparation of drug for prevention and treatment of thromboembolic diseases |
-
2004
- 2004-05-20 CN CN 200410038284 patent/CN1579415A/zh active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150051165A1 (en) * | 2012-03-05 | 2015-02-19 | Shanghai Kairun Biology Medicine Limited Liability Company | Application of depolymerized holothurian gylcosaminoglycans (dhg) in preparation of drug for prevention and treatment of thromboembolic diseases |
US9539271B2 (en) * | 2012-03-05 | 2017-01-10 | Shanghai Kairun Biology Medicine Limited Liability Company | Application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of drug for prevention and treatment of thromboembolic diseases |
CN103536621A (zh) * | 2012-07-11 | 2014-01-29 | 上海开润生物医药有限公司 | 海参糖胺聚糖在制备治疗冠脉综合症药物中的应用 |
CN102993324A (zh) * | 2012-12-30 | 2013-03-27 | 青岛市市立医院 | 一种提取玉足海参糖胺聚糖的方法 |
CN102993325A (zh) * | 2012-12-30 | 2013-03-27 | 青岛市市立医院 | 一种从刺参中提取糖胺聚糖的方法 |
CN104147039A (zh) * | 2013-05-13 | 2014-11-19 | 上海开润生物医药有限公司 | 黑海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
CN104147040A (zh) * | 2013-05-13 | 2014-11-19 | 上海开润生物医药有限公司 | 海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
WO2014183466A1 (zh) * | 2013-05-13 | 2014-11-20 | 上海开润生物医药有限公司 | 海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2794666B1 (en) | Use of chemically modified heparin derivates in sickle cell disease | |
AU634730B2 (en) | Antithrombotic composition | |
US5116963A (en) | High-purity dermatan sulphate | |
CN1579415A (zh) | 玉足海参糖胺聚糖针剂及其制备方法 | |
KR102082276B1 (ko) | 고순도 헤파린 및 그 제조방법 | |
US9539271B2 (en) | Application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of drug for prevention and treatment of thromboembolic diseases | |
SU581872A3 (ru) | Способ получени ферментного препарата, обладающего гемостатическим и антикоагулирующим действием | |
US6127347A (en) | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes | |
JP3813169B2 (ja) | 抗血栓剤 | |
Lu et al. | The research progress of antitumorous effectiveness of Stichopus japonicus acid mucopolysaccharide in north of China | |
CN100593420C (zh) | 一种内皮抑素结合物及其制备方法 | |
CN102191305A (zh) | 一种蹄甲多肽的复合水解制备方法 | |
KR101780643B1 (ko) | 효소분해를 이용한 헤파린의 정제 방법 | |
CN106589149B (zh) | 一种苦瓜多糖的提取方法及其产品、应用 | |
US20110263527A1 (en) | Sulfated Galactans With Antithrombotic Activity, Pharmaceutical Composition, Method for Treating or Prophylaxis of Arterial or Venous Thrombosis, Method of Extraction and Use Thereof | |
CN102973526A (zh) | 人抗凝血酶制剂冷冻干燥过程中的保护剂 | |
KR102298179B1 (ko) | 비분획 헤파린의 제조방법 | |
CN107011464A (zh) | 一种高效的粗品肝素钠生产工艺 | |
CN1218747C (zh) | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 | |
CN101880656A (zh) | 一种蝮蛇毒凝血酶及其制备方法和应用 | |
CN103536621A (zh) | 海参糖胺聚糖在制备治疗冠脉综合症药物中的应用 | |
CN1562147A (zh) | 黄芩提取物冻干粉针剂及其制备方法 | |
CN1255122C (zh) | 红景天冻干粉针剂及其制备方法 | |
JP2003252906A (ja) | 硫酸化フコビオシルコンドロイチン硫酸誘導体 | |
JPH08109140A (ja) | 高血圧症予防治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJING HONGDOUSHAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHEN RENZHONG Effective date: 20050624 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050624 Address after: 150000, Heilongjiang Economic Development Zone, No. 2 Wuyi Road, Heilongjiang red bean unlined garment Co., Ltd. Applicant after: Heilongjiang red bean sweater Pharmaceutical Co., Ltd. Address before: Changzhou City, Jiangsu province 213003 Yanling West Road No. 66 8 floor Applicant before: Chen Renzhong |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |